Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Price, News & Analysis

Prometheus Biosciences logo

About Prometheus Biosciences Stock (NASDAQ:RXDX)

Key Stats

Today's Range
$199.92
$199.92
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
N/A
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Stock News Headlines

Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
Prometheus Biosciences (NASDAQ: RXDX)
See More Headlines

RXDX Stock Analysis - Frequently Asked Questions

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.06. The business's revenue was down 71.8% compared to the same quarter last year.

The following companies are subsidiaries of Prometheus Biosciences: Prometheus Laboratories Inc..

Prometheus Biosciences (RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prometheus Biosciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Moderna (MRNA).

Company Calendar

Last Earnings
5/09/2023
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
97
Year Founded
1995

Profitability

Net Income
$-141,750,000.00
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Book Value
$16.12 per share

Miscellaneous

Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:RXDX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners